<div id="readability-page-1"><p><span>Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report)</span> had its price target lifted by HC Wainwright  from $568.00 to $620.00 in a report issued on Friday,Benzinga reports. The firm currently has a &#34;buy&#34; rating on the biopharmaceutical company's stock. HC Wainwright's price target points to a potential upside of 11.96% from the stock's previous close.</p><ul><li>MarketBeat Week in Review – 09/08 - 09/12</li></ul><p>Other research analysts also recently issued research reports about the company. UBS Group  restated a &#34;buy&#34; rating and issued a $523.00 target price (up previously from $458.00) on shares of Madrigal Pharmaceuticals in a research note on Tuesday, August 12th. Citigroup  reiterated an &#34;outperform&#34; rating on shares of Madrigal Pharmaceuticals in a report on Wednesday, November 5th. Piper Sandler boosted their price target on Madrigal Pharmaceuticals from $400.00 to $540.00 and gave the company an &#34;overweight&#34; rating in a research note on Wednesday, October 15th. B. Riley increased their price objective on Madrigal Pharmaceuticals from $460.00 to $560.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, September 29th. Finally, Citizens Jmp raised their price objective on shares of Madrigal Pharmaceuticals from $485.00 to $527.00 and gave the company a &#34;market outperform&#34; rating in a research report on Wednesday, November 5th. Thirteen equities research analysts have rated the stock with a Buy rating, one  has issued  a Hold rating and one  has issued  a Sell rating to the stock. Based on data from MarketBeat, Madrigal Pharmaceuticals  has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $553.50.</p><p><b>View Our Latest Research Report on MDGL</b></p><h2>Madrigal Pharmaceuticals Trading Up 2.1%</h2><ul><li>CoreWeave and Madrigal's Insider Trades Flash Bullish Signals</li></ul><p>Shares of Madrigal Pharmaceuticals stock traded up $11.65 during trading on Friday, hitting $553.77. The stock had a trading volume of 108,002 shares, compared to its average volume of 370,878. Madrigal Pharmaceuticals has a 1 year low of $265.00 and a 1 year high of $577.90. The stock has a 50 day simple moving average of $454.65 and a 200 day simple moving average of $370.97. The company has a quick ratio of 4.78, a current ratio of 5.11 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $12.58 billion, a PE ratio of -43.23 and a beta of -1.04. </p><p>Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($5.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.01) by ($3.07). Madrigal Pharmaceuticals had a negative return on equity of 38.38% and a negative net margin of 54.68%. On average, research analysts expect that  Madrigal Pharmaceuticals will post -23.47 EPS for the current fiscal year. </p><h2>Insider Buying and Selling</h2><ul><li>Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon</li></ul><p>In other news, Director Kenneth Bate sold 16,575 shares of the stock in a transaction that occurred on Wednesday, November 5th. The stock was sold at an average price of $484.30, for a total value of $8,027,272.50. Following the completion of the sale, the director directly owned 2,627 shares of the company's stock, valued at approximately $1,272,256.10. This represents a 86.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, Director Richard S. Levy sold 8,500 shares of the firm's stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $520.96, for a total transaction of $4,428,160.00. Following the completion of the sale, the director owned 21,197 shares in the company, valued at approximately $11,042,789.12. The trade was a 28.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 32,354 shares of company stock valued at $15,699,173. Insiders own  21.50% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>Several institutional investors and hedge funds have recently made changes to their positions in the stock. Envestnet Asset Management Inc. increased its holdings in  Madrigal Pharmaceuticals by 1.8% in the 1st quarter. Envestnet Asset Management Inc. now owns 15,270 shares of the biopharmaceutical company's stock valued at $5,058,000 after buying an additional 269 shares during the period.  Allianz Asset Management GmbH boosted its position in shares of  Madrigal Pharmaceuticals by 59.1% during the 1st quarter. Allianz Asset Management GmbH now owns 1,556 shares of the biopharmaceutical company's stock valued at $515,000 after acquiring an additional 578 shares in the last quarter.  Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in  Madrigal Pharmaceuticals in the first quarter valued at about $652,000.  Assetmark Inc. increased its stake in  Madrigal Pharmaceuticals by 24.0% in the first quarter. Assetmark Inc. now owns 5,183 shares of the biopharmaceutical company's stock valued at $1,717,000 after acquiring an additional 1,003 shares during the period.  Finally, LPL Financial LLC raised its position in  Madrigal Pharmaceuticals by 490.5% in the first quarter. LPL Financial LLC now owns 30,822 shares of the biopharmaceutical company's stock worth $10,209,000 after purchasing an additional 25,602 shares in the last quarter. Institutional investors own  98.50% of the company's stock. </p><h2>About Madrigal Pharmaceuticals</h2> (Get Free Report)<p>Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.</p><h2>See Also</h2><ul><li>Five stocks we like better than Madrigal Pharmaceuticals</li><li>Financial Services Stocks Investing</li><li>4 High-Risk Growth Stocks Under $15 to Watch This Fall</li><li>What Are the U.K. Market Holidays? How to Invest and Trade</li><li>Walmart Stock Surges After a Solid Q3—Stronger Growth Ahead</li><li>Find and Profitably Trade Stocks at 52-Week Lows</li><li>Microsoft’s AI Superfactory Could Power a Stock Rally</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURHTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURHTA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Madrigal Pharmaceuticals Right Now?</h2><p>Before you consider Madrigal Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Madrigal Pharmaceuticals wasn't on the list.</p><p>While Madrigal Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

MDGL

<p>HC Wainwright raised Madrigal Pharmaceuticals' price target from $568 to $620, maintaining a "buy" rating, indicating an 11.96% potential upside. Other analysts also issued positive ratings, with a consensus target price of $553.50. Madrigal's stock rose 2.1% to $553.77. The company reported a quarterly EPS of ($5.08), missing estimates. Insider trading saw significant stock sales, and institutional investors adjusted their positions. Madrigal has a market cap of $12.58 billion and a negative PE ratio of -43.23.</p>

Madrigal Pharmaceuticals (NASDAQ:MDGL) Given New $620.00 Price Target at HC Wainwright